DBV Technologies Updates on Liquidity Contract
DBV Technologies, a leader in developing innovative treatments for food allergies, recently published an important update regarding its liquidity contract with ODDO BHF. This report covers the assets in the liquidity account as well as trading activities during the specified period, shedding light on the company’s financial health and operational focus.
Assets in the Liquidity Account
As of December 31, 2024, the liquidity contract reflected a balance of 266,868 shares belonging to DBV Technologies, valued at €106,930.51. This signifies a robust position within the liquidity market that supports the company’s strategic initiatives.
In contrast, upon the implementation of the liquidity contract on July 1, 2018, there were previously 41,159 shares, alongside an initial valuation of €432,367.25. This showcases significant growth and an effective management of liquidity resources over time.
Trading Activity Overview
During the six-month period from July 1, 2024, to December 31, 2024, DBV Technologies executed a total of 1,682 buy transactions and 1,800 sales transactions. This trading volume amounted to 404,081 shares and €296,390.97 in purchases, whereas the sales transactions accounted for 440,957 shares and €340,906.76.
Understanding DBV Technologies
Founded in Châtillon, France, DBV Technologies is pioneering clinical-stage biopharmaceutical advancements, specializing in solutions for food allergies and other serious immunologic conditions. The firm is particularly concentrated on its Viaskin® patch technology, enhancing the treatment landscape for individuals suffering from food allergies through non-invasive methods.
Viaskin® functions through epicutaneous immunotherapy (EPIT™), aiming to induce a tolerance to specific allergens by training the immune system via microdoses absorbed through the skin. This technology is vital for countless children struggling with food allergies, a condition that greatly impacts daily life and can lead to severe health implications.
Ongoing Clinical Trials
DBV Technologies is actively engaged in clinical trials utilizing Viaskin® Peanut, primarily aimed at peanut-allergic toddlers and children. These efforts illustrate the company’s commitment to addressing unmet medical needs and enhancing quality of life for patients and their families.
Strategic Focus and Future Directions
As the biopharmaceutical landscape continues to evolve, DBV Technologies remains steadfast in its mission to innovate and deliver groundbreaking treatment modalities. The company is not just focused on immediate clinical applications but also seeks to explore further opportunities in immunotherapy and similar therapeutic areas.
Currently, the firm’s share of market trading is depicted on the Euronext Paris under the ticker DBV (ISIN code: FR0010417345) and on the Nasdaq Capital Market under the ticker DBVT. This dual presence broadens their investor outreach and capital traffic, ensuring sustained growth and transparency in their operations.
Investor Relations and Media Contact
For those interested in deeper insights or further updates, DBV Technologies maintains a proactive communication channel. Investor inquiries can be directed to Katie Matthews at DBV Technologies, and media inquiries can be sent to Angela Marcucci.
To stay informed on the latest developments or for investor relations, you can connect with them through their official channels.
Frequently Asked Questions
What is the focus of DBV Technologies?
DBV Technologies is focused on developing treatments for food allergies and other immunologic conditions using innovative patch technology.
What does the liquidity contract entail?
The liquidity contract with ODDO BHF involves managing the buying and selling of shares to enhance market visibility and stabilize share price actions.
How many shares are currently held under the liquidity contract?
As of December 31, 2024, DBV Technologies holds 266,868 shares under the liquidity contract.
What is the purpose of Viaskin® technology?
Viaskin® is designed for epicutaneous immunotherapy, delivering allergenic substances through the skin to re-educate the immune system.
Who can I contact for more information?
For investor or media inquiries, you can contact Katie Matthews for investors and Angela Marcucci for media relations at DBV Technologies.
